YL-13027 in Patients With Advanced Solid Tumors
NCT05228600
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
YL-13027
Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Collaborators
[object Object]